Site growth

Should you sell your research site? Questions to ask first

By TrialNotice · Updated
Research site leaders reviewing performance metrics on a large screen in a meeting room
Short answerBefore selling a research site, ask what you want next, what the site is worth today versus after fixing its weak spots, what you give up in control and patient relationships, how the deal is paid out, and what happens to your staff. Buyers pay most for scale, backlog, diversified sponsors, investigator depth, and proven enrollment, so improving those first can change the outcome.
This is general information, not financial or legal advice. Work with an experienced advisor and attorney on any transaction.

Why are owners asking this now?

Because buyers are active. Private equity backed networks and strategic acquirers have been rolling up independent sites (Objective IBV), while standalone sites face rising costs and a softer flow of new studies (Bourne Partners). Both push owners to consider their options.

What questions should you answer first?

  1. What do you want next? Retirement, more capital to grow, less administrative work, or staying on as PI.
  2. What is the site worth today? Standalone sites under $5 million EBITDA most often trade at 4x to 6x (Objective IBV).
  3. What would raise that value in 12 to 24 months? More investigators, more sponsors, a larger backlog, documented patient access.
  4. Who controls studies and patients after the sale? Study allocation, therapeutic focus, and your referral relationships may move to the buyer.
  5. How is the price paid? Cash at close versus payments tied to future performance or rolled equity.
  6. What happens to your staff? Retention, roles, and pay.
  7. What do critics worry about? A private equity watchdog has raised concerns about consolidation's effects on patients and costs (Private Equity Stakeholder Project). Know how a buyer operates.

What weak spots cost owners the most?

  • Dependence on one principal investigator.
  • Revenue concentrated in one sponsor or CRO.
  • Unresolved compliance findings.
  • Enrollment that depends on one person's relationships (Objective IBV).

What can you fix before deciding?

Enrollment predictability is the most fixable. A documented physician referral program, with practices, specialties, and referral volume tracked, turns patient access into an asset a buyer can verify, and it improves the business whether or not you sell. See how private equity values a site.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Objective Investment Banking and Valuation, "Valuation of Clinical Research Sites: What Buyers Look For"
  2. Private Equity Stakeholder Project, "Private equity moves into clinical trials" (November 2025)
  3. Bourne Partners, "Update on the Fundamentals of Clinical Trial Sites" (SCRS Global Site Solutions Summit takeaways, October 2025)

Keep reading

Two clinical research site staff members reviewing a growth plan together in a bright office
Site growth

How to grow a clinical research site: a practical playbook

Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.

 Research site director presenting enrollment results to sponsor representatives across a conference table
Site growth

How research sites get more studies from sponsors and CROs

Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.

 Sponsor clinical operations team reviewing site maps and performance charts on a large screen
Site growth

How sponsors and CROs select clinical trial sites

Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.